Causes and complications among patients with cirrhosis in Guilan province, Iran
DOI:
https://doi.org/10.61882/MEJNCD.1.1.1Keywords:
Cirrhosis, Non-alcoholic fatty liver disease, Hepatitis, Autoimmune liver disease, Metabolic syndromeAbstract
Background: Cirrhosis presents with various etiologies and complications that may differ between individuals. This study aimed to evaluate causes and complications in patients with cirrhosis.
Method: This cross-sectional study was conducted on 308 patients with cirrhosis in Guilan province, Iran. Patient data including demographics, cirrhosis etiology, complications, and laboratory findings were recorded. Statistical analysis was performed using SPSS software version 20 with significance set at P < 0.05.
Results: Out of 308 liver cirrhosis cases, 68.2% were male, with a mean age of 59.29±15.1 years, predominantly urban residents (81.5%). Non-alcoholic fatty liver disease/ metabolic syndrome (NAFLD/MetS) was the leading cause (47.7%), with a higher prevalence in males (59.6%, P=0.004), while autoimmune liver disease was more frequent in females (P < 0.001).Viral hepatitis contributed significantly, with hepatitis B virus (HBV) and C (HCV) in 17.9% and 9.7% of cases, respectively, both showing male predominance. Ascites were the most common complication (82.8%), significantly associated with age (P = 0.015). Esophageal varices (54.6%) and variceal bleeding (26%) were linked to age and longer disease duration (P < 0.001). Other complications, including hepatic encephalopathy (33.5%), hepatocellular carcinoma (7.2%), and portal vein thrombosis (10%), showed no significant trends with age,gender, or disease duration (P > 0.05).
Conclusion: Liver cirrhosis demonstrated distinct patterns based on gender and age,highlighting the need for personalized care. The causes and complications related to cirrhosis underscored the importance of demographic-specific approaches in prevention, early detection,and management to optimize outcomes for cirrhosis patients
References
1. Battle A, Mudd J, Ahlenstiel G, Kalo E. Liver Cirrhosis: Evolving Definitions, and Recent Advances in Diagnosis, Prevention and Management. Livers. 2025;5(3):28. DOI: 10.3390/livers5030028
2. Luo X, He Y, Jiang Z, Liao J. Global burden of liver cirrhosis: trends from 1990-2021 and projections to 2060. J Health Popul Nutr. 2025;44(1):370. DOI: 10.1186/s41043-025-01109-5 PMID: 41126322
3. Wu XN, Xue F, Zhang N, Zhang W, Hou JJ, Lv Y, et al. Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019. BMC Public Health. 2024;24(1):363.
DOI: 10.1186/s12889-024-17948-6 PMID: 38310221
4. Younossi ZM, Wong G, Anstee QM, Henry L. The Global Burden of Liver Disease. Clin Gastroenterol Hepatol. 2023;21(8):1978-1991. DOI: 10.1016/j.cgh.2023.04.015 PMID: 37121527
5. Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388-398.
DOI: 10.1038/s41575-023-00759-2 PMID: 36977794
6. Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol. 2021;27(36):6025-6038.
DOI: 10.3748/wjg.v27.i36.6025 PMID: 34629817
7. Amini-Salehi E, Letafatkar N, Norouzi N, Joukar F, Habibi A, Javid M, et al. Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries. Arch Med Res. 2024;55(6):103043.
DOI: 10.1016/j.arcmed.2024.103043 PMID: 39094335
8. Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021;113(3):170-184.
DOI: 10.32074/1591-951X-245 PMID: 34294935
9. Kalurazi TY, Shakoori V, Nasiri S, Foumani AA, Hesni E, Mahfoozi L, et al. Clinical characteristics and laboratory findings of patients with COVID-19 in Rasht, Iran. J Curr Biomed Rep. 2022;3:91-7. DOI: 10.52547/JCBioR.3.2.91
10. Haghighi M, Khoshrang H, Rimaz S, Kalurazi TY, Atrkar Z, Roushan SG, et al. Evaluation of sequential organ failure assessment (SOFA) score efficiency in predicting the mortality of intensive care unit admitted COVID-19 patients. J Curr Biomed Rep. 2021;2(4):168-75. DOI: 10.52547/JCBioR.2.4.168
11. Ashoobi MT, Joukar F, Mojtahedi K, Maroufizadeh S, Javid M, Parvaneh A, et al. Elevated liver enzymes and diabetes in the PERSIAN Guilan cohort study. Caspian J Intern Med. 2024;16(1):73-82. DOI: 10.22088/cjim.16.1.73 PMID: 39619755
12. Alizadeh A, Joukar F, Ghorani N, Mansour Ghanaei A, Tabatabaii MJ, Faraji N, et al. Prevalence of Hepatic Space-Occupying Lesions Based on Sonographic Findings in Patients Referred to Guilan Cohort Center, Iran. Hepatitis Mon. 2022;22(1):e124888. URL: https://sid.ir/paper/987323/en
13. Baumert LS, Shih A, Chung RT. Management of liver disease and portal hypertension in common variable immunodeficiency (CVID). JHEP Rep. 2023;5(11):100882.
DOI: 10.1016/j.jhepr.2023.100882 PMID: 37869072
14. Sharma B, John S. Hepatic Cirrhosis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
PMID: 29494026
15. De Gaetano V, Pallozzi M, Cerrito L, Santopaolo F, Stella L, Gasbarrini A, et al. Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives. Cancers (Basel). 2024;16(7):1388.
DOI: 10.3390/cancers16071388 PMID: 38611066
16. Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…. Liver Int. 2021;41(8):1734-1743.
DOI: 10.1111/liv.14977 PMID: 34051060
17. Floreani A, Gabbia D, De Martin S. Are Gender Differences Important for Autoimmune Liver Diseases? Life (Basel). 2024;14(4):500. DOI: 10.3390/life14040500 PMID: 38672770
18. Matz-Soja M, Berg T, Kietzmann T. Sex-related variations in liver homeostasis and disease: From zonation dynamics to clinical implications. J Hepatol. 2025;S0168-8278(25)02442-0.
DOI: 10.1016/j.jhep.2025.08.007 PMID: 40846185
19. Nevola R, Tortorella G, Rosato V, Rinaldi L, Imbriani S, Perillo P, et al. Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma. Biology (Basel). 2023;12(7):984. DOI: 10.3390/biology12070984 PMID: 37508414
20. Shahdkar M, Goorabzarmakhi MO, Shafizadeh M, Joukar F, Maroufizadeh S, Faraji N, et al. Association between dyslipidemia and elevated liver enzymes: A cross-sectional study from the PERSIAN Guilan cohort study. Endocr Metab Sci. 2025:100272. DOI: 10.1016/j.endmts.2025.100272
21. Zhu L, Spence C, Yang JW, Ma GX. The IDF Definition Is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011-2016. J Clin Med. 2020;9(12):3871.
DOI: 10.3390/jcm9123871 PMID: 33260754
22. Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J Gastroenterol. 2022;28(41):5910-5930.
DOI: 10.3748/wjg.v28.i41.5910 PMID: 36405106
23. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516-537.
DOI: 10.1016/j.jhep.2023.03.017 PMID: 36990226
24. Tan D, Chan KE, Wong ZY, Ng CH, Xiao J, Lim WH, et al. Global Epidemiology of Cirrhosis: Changing Etiological Basis and Comparable Burden of Nonalcoholic Steatohepatitis between Males and Females. Dig Dis. 2023;41(6):900-912.
DOI: 10.1159/000533946 PMID: 37703863
25. Kasarinaite A, Sinton M, Saunders PTK, Hay DC. The Influence of Sex Hormones in Liver Function and Disease. Cells. 2023;12(12):1604.
DOI: 10.3390/cells12121604 PMID: 37371074
26. Choudhary NS, Duseja A. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How? J Clin Exp Hepatol. 2019;9(4):506-514. DOI: 10.1016/j.jceh.2019.02.005 PMID: 31516267
27. Bashir A, Duseja A, De A, Mehta M, Tiwari P. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. Liver Res. 2022;6(2):72-83.
DOI: 10.1016/j.livres.2022.05.002 PMID: 39958625
28. Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med. 2016;32(5):329-334.
DOI: 10.1159/000448940 PMID: 27921044
29. Pisaturo M, Onorato L, Russo A, Coppola N. Prevalence of occult HBV infection in Western countries. J Med Virol. 2020;92(12):2917-2929.
DOI: 10.1002/jmv.25867 PMID: 32275083
30. Poovorawan K, Soonthornworasiri N, Sa-Angchai P, Mansanguan C, Piyaphanee W. Hepatitis B vaccination for international travelers to Asia. Trop Dis Travel Med Vaccines. 2016;2:14. DOI: 10.1186/s40794-016-0031-z PMID: 28883958
31. Lloyd AR, Franco RA. Sexual Transmission of Viral Hepatitis. Infect Dis Clin North Am. 2023;37(2):335-349.
DOI: 10.1016/j.idc.2023.02.010 PMID: 37105646
32. Li C, Thapa D, Mi Q, Gao Y, Fu X. Disparities in hepatitis B virus healthcare service access among marginalised poor populations: a mixed-method systematic review. Infect Dis Poverty. 2024;13(1):58.
DOI: 10.1186/s40249-024-01225-0 PMID: 39123232
33. Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res. 2022;7:32.
DOI: 10.12688/wellcomeopenres.17601.3 PMID: 36212217
34. Le TV, Vu TTM, Mai HT, Nguyen LH, Truong NT, Hoang CL, et al. Social Determinants of Stigma and Discrimination in Vietnamese Patients with Chronic Hepatitis B. Int J Environ Res Public Health. 2019;16(3):398. DOI: 10.3390/ijerph16030398 PMID: 30708943
35. Invernizzi F, Cilla M, Trapani S, Guarino M, Cossiga V, Gambato M, et al. Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. J Pers Med. 2022;12(6):925.
DOI: 10.3390/jpm12060925 PMID: 35743710
36. Yang Q, Kennicott K, Zhu R, Kim J, Wakefield H, Studener K, et al. Sex hormone influence on female-biased autoimmune diseases hints at puberty as an important factor in pathogenesis. Front Pediatr. 2023;11:1051624. DOI: 10.3389/fped.2023.1051624 PMID: 36793337
37. Sohail R, Hassan IH, Rukh M, Saqib M, Iftikhar M, Mumtaz H. Assessing Thrombocytopenia and Chronic Liver Disease in Southeast Asia: A Multicentric Cross-Sectional Study. Cureus. 2023;15(8):e43356.
DOI: 10.7759/cureus.43356 PMID: 37700968
38. Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37(6):778-793. DOI: 10.1111/liv.13317 PMID: 27860293
39. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50.
DOI: 10.2147/HMER.S74612 PMID: 27186144
40. Haukeland JW, Småstuen MC, Pålsdatter PP, Ismail M, Konopski Z, Jørgensen KK, et al. Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway. PLoS One. 2020;15(3):e0230263. DOI: 10.1371/journal.pone.0230263 PMID: 32163489
41. Hosseini-Ghaziani SK, Shafaghi A, Joukar F, Letafatkar N, Habibi A, Maroufizadeh S, et al. Platelet count/spleen diameter ratio for the non-invasive diagnosis of esophageal varices in Iranian patients with cirrhosis: Platelet count/spleen diameter ratio and esophageal varices. J Curr Oncol Med Sci. 2024;4(3):883-90. URL:http://submission.journalofcoms.com/index.php/JCOMS/article/view/237
42. Zhang X, Wong GL, Yip TC, Cheung JTK, Tse YK, Hui VW, et al. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology. 2022;76(5):1409-1422. DOI: 10.1002/hep.32476 PMID: 35334125
43. Georgieva M, Xenodochidis C, Krasteva N. Old age as a risk factor for liver diseases: Modern therapeutic approaches. Exp Gerontol. 2023;184:112334. DOI: 10.1016/j.exger.2023.112334 PMID: 37977514
Downloads
Published
Issue
Section
License
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
